MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Medincell's (Paris:MEDCL) partner, Teva Pharmaceuticals, today shared the following information in connection with the publication of its Q4 and fullyear 2025 results: About UZEDY® 2025 net sales reached $191 million, including$55 million in the fourth quarter Teva's initial 2026 net sales outlook is in the range of $250 -$280 million Medincell receives midto highsingle-digit royalties on UZEDY® net sales and is eligible for up to $105. ...